Clinical effect of human-fibroblast-derived (Beta) interferon in treatment of adeno-virus epidemic keratoconjunctivitis and its complications.
The clinical studies reviewed here indicated the usefulness of topical application of Human-fibroblast-derived (Beta) interferon (Hu1FN-B) in treatment of Adeno-8 Epidemic-keratoconjunctivitis. A week treatment with 2-5 x 10(5) reference units daily doses, starting early as possible, reduced the length of the disease from 22 day to a week, and almost totally prevented the appearance of subepithelial keratitis which occurred in 57% of the control group. Possibly interferon should be given also prophylactically to individuals exposed to contagion. Our results encourage further investigation on the Hu1 FN-B use as a drug for treatment and prevention of viral infection.
D000257:Adenoviridae Infections / Q000628:therapy*; D000258:Adenovirus Infections, Human / Q000628:therapy*; D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use*; D007637:Keratoconjunctivitis / Q000628:therapy*; D008297:Male; D009883:Ophthalmic Solutions; D013997:Time Factors
D007370:Interferon Type I; D009883:Ophthalmic Solutions